LUXEMBOURG--(BUSINESS WIRE)--Feb 27, 2025--
Following a 2024 contract award from NATO Support and Procurement Agency (NSPA), SES started providing Medium Earth Orbit (MEO) Global Services to Luxembourg and U.S. governments via its O3b mPOWER constellation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250226385020/en/
Known as MEO Global Services (MGS), the contract awarded within NSPA’s Global Commercially Contracted SATCOM Support Partnership (GCC SATCOM SP) initiated by the US and Luxembourg, allows NATO Members and NATO Partners participating to the agreement to build sovereign networks, or utilise fully-managed low-latency, high-performance satellite communications service.
SES’s MEO connectivity is enabling government organisations, agencies and militaries at global missions on land, at sea and in the air to run real-time applications like HD video calls and uninterrupted simultaneous downloads of other data-intensive applications in the background reliably.
In the framework of MGS, the United States plan to install six MEO Sovereign Gateways in various locations across the globe, to ensure secure and resilient connectivity globally.
Furthermore, in January 2025, The Netherlands officially joined the GCC SATCOM SP, underscoring growing multinational collaboration.
Yuriko Backes, Luxembourg’s Minister of Defence: “Enhancing secure and resilient satellite communications for defence and allied operations remains a priority for Luxembourg. Through MGS and the framework of the GCC SATCOM Support Partnership, we are leveraging SES’s state of the art O3b mPOWER constellation to ensure high-performance satellite communication to support national requirements and put them to the benefit of NATO nations and our partners. We welcome our Ally the Netherlands joining this collaborative space endeavour.”
“The progress of the GCC SATCOM Support Partnership highlights the power of multinational cooperation in the space domain. By working together, participating nations gain access to secure, advanced satellite communications that enhance interoperability and operational flexibility. The addition of the Netherlands underscores the growing value of this partnership in strengthening NATO’s space capabilities,” said Stacy Cummings, NSPA General Manager.
U.S. Space Force Brig. Gen. Jacob Middleton, Commander of U.S. Space Forces Europe and Space Forces Africa: “Integrating directly with Allies and partners through joint endeavors, such as the GCC SATCOM Support Partnership, builds trust, facilitates information sharing, and fosters a deeper understanding of common strengths and challenges. Increasing space capabilities through multinational cooperation is important to the region’s deterrence and defense.”
Colonel Bernard Buijs, Head of Defence Space Security Centre, The Netherlands: “The best way to prevent a conflict is to keep communicating! To make this happen, the Netherlands firmly believes in the value of international cooperation, and through initiatives like the GCC SATCOM SP by NSPA, nations can come together to share expertise, leverage resources, and acquire unique capabilities that might be out of reach individually.”
SES’s CEO Adel Al-Saleh: “Low latency, guaranteed service level agreements, flexibility and security of communications underscore O3b mPOWER’s advantages as the capability of choice when it comes to serving the NATO nations. We are delighted to start delivering connectivity to the MGS founding countries, as well as to welcome new countries under the NSPA agreements.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
SES’s O3b mPOWER Now Providing Connectivity Services to Governments via NSPA’s MGS (Photo: Business Wire)
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Jun 8, 2026--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/
Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL.
“With Deora™, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. "We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up. Our belief has been supported by early customer interest, and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities.”
The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing.
“Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” added Michele Monico. “Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs.”
Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners.
Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Forward-Looking Statements
This press release may include forward-looking statements. The words “strong”, “experiencing”, “believe”, “are providing”, “position”, “advance”, “intended”, “prepare”, “future”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.
Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull‑push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners
